The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial-Reference-Cited by-同舟云学术

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial

Published:2003-08 Issue:8 Volume:9 Page:529-539
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Stiff Patrick J,Unger Joseph M,Forman Stephen J,McCall Anne R,LeBlanc Michael,Nademanee Auayporn P,Bolwell Brian J,Fisher Richard I

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference58 articles.

1. Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse;Fisher;Ann Intern Med,1979

2. Conventional-dose salvage combination chemotherapy in patients relapsing after conventional chemotherapy;Longo;J Clin Oncol,1992

3. Dexamethasone, high dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin’s disease;Velasquez;Blood,1986

4. Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug regimens;Dfreundschuh;J Clin Oncol,1994

5. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD;Bonfante;J Clin Oncol,1994

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunochemotherapy of refractory classical Hodgkin's lymphoma with high-dose consolidation and autologous hematopoietic stem cell transplantation complicated by a new coronavirus infection;Oncohematology;2022-07-20

2. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells;Frontiers in Immunology;2021-11-05

3. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma;Journal for ImmunoTherapy of Cancer;2021-04

4. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma;Cancers;2020-10-08

5. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2020-06